Albireo Pharma, Inc. (ALBO) financial statements (2021 and earlier)

Company profile

Business Address 10 POST OFFICE SQUARE
BOSTON, MA 02109
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
9/30/2016
9/30/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments25113216453302941
Cash and cash equivalents25113216453302941
Receivables  310  
Other undisclosed current assets111011100
Total current assets:26214216855312941
Noncurrent Assets
Property, plant and equipment01000 0
Intangible assets, net (including goodwill)171717171800
Goodwill1717171718  
Intangible assets, net (excluding goodwill)    000
Other noncurrent assets65011  
Total noncurrent assets:242318181900
TOTAL ASSETS:28616518573502941
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2418137912
Accounts payable5541100
Accrued liabilities191386800
Employee-related liabilities     01
Debt    3  
Derivative instruments and hedges, liabilities    1  
Restructuring reserve     1 
Other liabilities11000  
Other undisclosed current liabilities    000
Total current liabilities:25191381322
Noncurrent Liabilities
Long-term debt and lease obligation134     
Long-term debt, excluding current maturities10      
Operating lease, liability44
Liabilities, other than long-term debt, including:4400 00
Other liabilities44 0 00
Other undisclosed liabilities, other than long-term debt  0    
Other undisclosed noncurrent liabilities624550  00
Total noncurrent liabilities:7953500 00
Total liabilities:104726381322
Stockholders' equity
Stockholders' equity attributable to parent1819312365372640
Preferred stock      0
Common stock0000001
Additional paid in capital45624621511561288287
Accumulated other comprehensive income (loss)(9)6411  
Accumulated deficit(267)(159)(96)(50)(26)(262)(248)
Total stockholders' equity:1819312365372640
TOTAL LIABILITIES AND EQUITY:28616518573502941

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
9/30/2016
9/30/2015
Revenue, net011  
Gross profit:81013011  
Operating expenses(105)(71)(51)(25)(24)(14)(20)
Operating loss:(96)(61)(38)(25)(12)(14)(20)
Nonoperating income (expense)154(3)0(3)  
Foreign currency transaction gain (loss), before tax15(4)(5)    
Loss from continuing operations before equity method investments, income taxes:(82)(57)(41)(24)(15)(14)(20)
Other undisclosed income (loss) from continuing operations before income taxes(26)(5)(5)0(1)01
Loss from continuing operations before income taxes:(108)(63)(46)(24)(16)(14)(19)
Income tax expense  (0)(0)(0)(0)(0)
Net loss available to common stockholders, diluted:(108)(63)(46)(24)(16)(14)(19)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
9/30/2016
9/30/2015
Net loss:(108)(63)(46)(24)(16)(14)(19)
Other comprehensive income (loss)(15)23(0)1  
Comprehensive loss, net of tax, attributable to parent:(123)(61)(43)(25)(16)(14)(19)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: